Intended Parents

IVF With Asherman syndrome: Success Rates, Treatment Options and When to Consider Surrogacy

IVF with Asherman syndrome can be successful if treatment leaves enough healthy uterine tissue for an embryo to implant and a pregnancy to develop.

IVF itself doesn’t remove uterine scar tissue or restore endometrium damaged by Asherman syndrome.

If you can create healthy embryos, your fertility specialist also needs to determine whether your uterus can support implantation and pregnancy.

That evaluation can help you decide whether treating Asherman syndrome and attempting another transfer makes sense or whether gestational surrogacy should be part of the conversation.

How Does Asherman syndrome Affect IVF?

Asherman syndrome can lower the chance of a successful IVF transfer when adhesions damage the uterine cavity or leave too little healthy endometrium for implantation.

These bands of scar tissue, called intrauterine adhesions, can change the shape of the uterine cavity and make implantation or continuing a pregnancy more difficult.

IVF doesn’t bypass this problem. Eggs can be retrieved and fertilized in a laboratory, but an embryo transferred during IVF still needs healthy, receptive endometrial tissue where it can implant.

Yale Medicine’s overview of Asherman syndrome and uterine scarring explains how adhesions can affect menstruation, fertility and pregnancy.

This is why egg quality, embryo quality and uterine receptivity need to be considered separately when considering IVF with Asherman syndrome. You may be able to produce good-quality embryos while still having a uterine factor that lowers the chance of a successful transfer.

A 2015 prospective study of 60 patients with Asherman syndrome found substantial differences based on disease severity. After hysteroscopic treatment, pregnancy rates were 53.8% among patients initially classified as having mild disease, compared with 26.9% for moderate disease and 9.5% for severe disease.

The study of reproductive outcomes also found higher pregnancy rates among patients with a normal endometrial pattern after treatment than among those with an altered pattern.

These aren’t IVF success rates and shouldn’t be used to predict your individual outcome.

The study included spontaneous pregnancies as well as assisted reproduction.

Its more useful finding for someone considering IVF is that the extent of the adhesions and the condition of the endometrium after treatment can make a meaningful difference in reproductive outcomes.

IVF Success Rates With Asherman syndrome

There isn’t one IVF success rate that applies to everyone with Asherman syndrome. Several factors can affect what another embryo transfer may realistically offer, including:

The severity and location of the adhesions
How much healthy endometrium remains after treatment
Whether adhesions return
Age
Embryo-related factors

A 2021 Fertility and Sterility study followed 500 women after hysteroscopic adhesiolysis for Asherman syndrome. Researchers reported 569 pregnancies within three years after surgery and a 67.4% live birth rate among those pregnancies.

The research on live births after Asherman’s treatment also found that lower-grade adhesions and younger age were associated with better reproductive outcomes.

The 67.4% figure isn’t a live birth rate per IVF embryo transfer. The researchers were looking at reproductive outcomes following surgical treatment of Asherman syndrome, so it can’t tell you that your next IVF transfer has a 67.4% chance of resulting in a live birth.

Differences in disease severity are one reason published outcomes can vary so much.

Someone with mild adhesions and healthy endometrium after surgery may have a very different prognosis from someone with extensive adhesions, recurrent scarring or lasting endometrial damage.

For IVF with Asherman syndrome, your post-treatment evaluation can give you more useful information than a broad success-rate statistic.

Ask your fertility specialist how much healthy endometrium remains, whether the adhesions have returned, how your lining responds during transfer preparation and what your estimated chance of live birth would be with another embryo transfer.

Treating Asherman syndrome Before IVF

Treating Asherman syndrome before IVF usually starts with hysteroscopic adhesiolysis.

During this procedure, a surgeon passes a hysteroscope through the cervix so the adhesions can be seen and separated directly, with the goal of restoring the uterine cavity while protecting healthy endometrial tissue.

Treatment often continues while the uterus heals because adhesions can form again.

RMA Network’s explanation of treatment for Asherman syndrome describes hysteroscopic surgery and the possibility that additional treatment may be needed when adhesions recur.

Depending on your condition and your physician’s protocol, treatment may include:

A balloon catheter: Temporarily separates the uterine walls while they heal.
An intrauterine device or another physical barrier: Some physicians use these to reduce contact between healing uterine surfaces.
Estrogen therapy: May be prescribed after surgery to encourage endometrial growth.
Follow-up hysteroscopy or imaging: Allows your physician to see whether the cavity remains open and whether adhesions have returned.

Some patients need more than one hysteroscopy.

In the 2015 study of 60 patients we discussed earlier, 38 underwent a second procedure because menstrual flow or endometrial appearance had not improved enough, while six underwent a third procedure.

If another surgery is being proposed before your next IVF transfer, ask what your doctor expects it to change. Another procedure may make sense when there is removable scar tissue and a reasonable chance of improving the uterine cavity.

If substantial endometrial damage remains, another adhesiolysis may not improve implantation prospects to the same degree.

Why Thin Endometrium Matters After Asherman syndrome

A persistently thin endometrium can reduce the chance of implantation after Asherman syndrome because the embryo needs receptive endometrial tissue to attach and develop.

Surgery may successfully reopen the uterine cavity without fully restoring the lining.

Asherman syndrome can damage the basal layer of the endometrium, which normally helps regenerate the lining.

RMIA’s discussion of endometrial lining and implantation illustrates why treating the adhesions and achieving adequate endometrial development are separate concerns before embryo transfer.

Your fertility clinic may adjust estrogen treatment or change the frozen embryo transfer protocol to see whether the lining responds. Some clinics also offer treatments such as platelet-rich plasma (PRP), but evidence for newer regenerative approaches is still developing.

Ask what evidence supports a proposed treatment and how much improvement your doctor realistically expects in your case.

Your doctor won’t necessarily make a transfer decision from one lining measurement. The appearance of the cavity, recurrence of adhesions, endometrial pattern, response to medication and results of previous transfers can provide a fuller picture of whether another transfer is reasonable.

Before proceeding with a frozen embryo transfer after Asherman syndrome treatment, your fertility clinic may reassess the uterine cavity and how the endometrium responds during transfer preparation.

If adhesions have returned or the lining still isn’t developing adequately, your doctor may recommend additional evaluation or treatment before transferring a frozen embryo.

If the lining remains persistently thin despite appropriate treatment, another transfer may leave the same uterine barrier in place.

At that point, asking whether transferring an embryo to a gestational surrogate would change the expected outcome can give you a more useful comparison.

When Do Fertility Specialists Recommend Surrogacy for Asherman syndrome?

Fertility specialists may recommend gestational surrogacy when Asherman syndrome leaves the uterus unable to safely or reliably support implantation and pregnancy, even though viable embryos can still be created or are already frozen.

Surrogacy can become medically appropriate because carrying the pregnancy is the primary barrier, not because you’ve reached a set number of unsuccessful IVF cycles.

Before recommending that change, your fertility clinic should evaluate what can still be improved in your uterus.

Hysteroscopy can assess the uterine cavity directly, while endometrial development, recurrence after treatment and previous pregnancy or transfer history can help clarify whether another attempt is likely to have a different outcome.

Surrogacy may deserve serious consideration when:

1
Severe adhesions remain after appropriate treatment.
2
Adhesions repeatedly return after hysteroscopic adhesiolysis.
3
The endometrium remains persistently thin or responds poorly to treatment.
4
Your fertility specialist doesn\'t expect another surgery to restore enough functional tissue.
5
Good-quality embryos haven\'t implanted and your clinic believes the uterine factor is the likely barrier.
6
Your physician believes uterine damage would make carrying a pregnancy medically unsafe or unlikely to result in a live birth.

Gestational surrogacy doesn’t replace IVF in this situation. IVF is still used to create embryos, or embryos you’ve already frozen may be used.

American Surrogacy’s discussion of IVF and Asherman syndrome provides additional context on why a gestational surrogate may be considered when the uterine factor continues to interfere with pregnancy.

Before deciding, ask your reproductive endocrinologist:

What evidence suggests my uterus is now the primary barrier?
What could another surgery or treatment realistically improve?
What is my estimated chance of live birth with another embryo transfer?
Would transferring an embryo to a medically cleared gestational surrogate materially change the prognosis?

Those answers are more useful than waiting until you’ve completed a certain number of transfers.

The relevant question is whether further treatment is likely to improve your ability to carry or whether transferring an embryo to a gestational surrogate would address the remaining medical barrier.

Why Surrogacy May Offer Better Odds Than Repeating IVF

Surrogacy may offer better odds than repeating an embryo transfer when viable embryos remain but persistent uterine damage is the primary barrier to pregnancy.

Another transfer doesn’t repair scar tissue or restore damaged endometrium, while gestational surrogacy changes the pregnancy-related factor your fertility specialist has identified as the problem.

This can matter even more if you have a limited number of frozen embryos.

Each additional transfer uses an embryo, so the expected benefit of another attempt deserves careful consideration when the condition of the uterus hasn’t meaningfully improved.

Surrogacy may also allow you to stop pursuing repeat uterine procedures when your fertility specialist believes another surgery has little chance of restoring enough functional endometrium.

Information on surrogacy with uterine scarring can help clarify why transferring an embryo to a gestational surrogate addresses a different part of the reproductive process than another uterine procedure or transfer.

Surrogacy doesn’t guarantee pregnancy, and embryo quality and other medical factors still affect the outcome.

It also introduces a different set of costs and steps, including surrogate matching and screening, legal representation, a Gestational Carrier Agreement, compensation, insurance review, escrow and fertility clinic expenses.

Compare those demands with what another round of treatment is expected to accomplish medically. If another surgery has a reasonable chance of restoring your ability to carry, continuing treatment may fit your goals.

If your clinic believes the uterine factor is unlikely to improve, discussing surrogacy sooner can help you decide how you want to approach your remaining embryos.

Common Misconceptions About IVF and Asherman syndrome

Several misconceptions about IVF with Asherman syndrome can make it harder to understand why a fertility clinic may recommend more uterine treatment in one case and gestational surrogacy in another.

Truth: IVF can create embryos outside the body, but it doesn\'t remove intrauterine adhesions or repair damaged endometrium. Yale Medicine\'s explanation of how Asherman\'s affects fertility provides more context on the relationship between uterine adhesions and difficulty becoming or remaining pregnant. A transferred embryo still needs receptive endometrial tissue to implant.

Truth: Hysteroscopic adhesiolysis can improve reproductive outcomes, but the result depends partly on the severity of the original damage and how the uterus heals. Adhesions can return, particularly after more extensive disease, and some patients need repeat procedures.

Truth: Additional embryos don\'t repair adhesions or make damaged endometrium more receptive. Embryo-transfer decisions should follow your fertility clinic\'s medical recommendations rather than treating additional embryos as a way around an unresolved uterine factor.

Truth: If IVF has produced viable embryos, embryo creation may not be the problem. Gestational surrogacy may be recommended because carrying the pregnancy has become the primary barrier. In that situation, surrogacy changes where the embryo is transferred rather than abandoning IVF.

Talk With a Surrogacy Professional About Your Next Step

A surrogacy professional can help you understand what gestational surrogacy would involve if your fertility clinic believes carrying the pregnancy has become the primary barrier.

You can learn about the process before deciding whether it makes more sense for you than further treatment or another embryo transfer.

Surrogacy works alongside IVF rather than replacing it.

A professional can explain how the process works with embryos you already have, expected timelines and costs, surrogate screening and matching and how your fertility clinic coordinates with the surrogacy process.

If you’re comparing another transfer with gestational surrogacy, information about finding a gestational surrogate can help you understand what screening, matching and the early stages of the process involve.

You and your fertility specialist can then weigh that information against what another Asherman’s treatment or embryo transfer is realistically expected to accomplish.

When carrying the pregnancy has become the main barrier, understanding both paths can help you choose your next step based on your medical circumstances and remaining family-building options.

Find Out More